JP7030716B2 - アレルギー治療に有用な細菌株の選択 - Google Patents
アレルギー治療に有用な細菌株の選択 Download PDFInfo
- Publication number
- JP7030716B2 JP7030716B2 JP2018558668A JP2018558668A JP7030716B2 JP 7030716 B2 JP7030716 B2 JP 7030716B2 JP 2018558668 A JP2018558668 A JP 2018558668A JP 2018558668 A JP2018558668 A JP 2018558668A JP 7030716 B2 JP7030716 B2 JP 7030716B2
- Authority
- JP
- Japan
- Prior art keywords
- dagk
- lactic acid
- strain
- acid bacterium
- reuteri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims description 44
- 230000001580 bacterial effect Effects 0.000 title description 114
- 206010020751 Hypersensitivity Diseases 0.000 title description 65
- 230000007815 allergy Effects 0.000 title description 53
- 208000026935 allergic disease Diseases 0.000 title description 19
- 108010062677 Diacylglycerol Kinase Proteins 0.000 claims description 136
- 102000011107 Diacylglycerol Kinase Human genes 0.000 claims description 135
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 90
- 241000894006 Bacteria Species 0.000 claims description 57
- 241000124008 Mammalia Species 0.000 claims description 48
- 235000014655 lactic acid Nutrition 0.000 claims description 45
- 239000004310 lactic acid Substances 0.000 claims description 45
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 39
- 230000001629 suppression Effects 0.000 claims description 34
- 230000002265 prevention Effects 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 238000012216 screening Methods 0.000 claims description 20
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 19
- 235000020932 food allergy Nutrition 0.000 claims description 19
- 101150030459 dagK gene Proteins 0.000 claims description 17
- 241000186660 Lactobacillus Species 0.000 claims description 13
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 13
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 210000000172 cytosol Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 description 34
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 17
- 230000001387 anti-histamine Effects 0.000 description 17
- 229940125715 antihistaminic agent Drugs 0.000 description 15
- 150000001982 diacylglycerols Chemical class 0.000 description 15
- 229960001340 histamine Drugs 0.000 description 15
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 14
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 14
- 239000006041 probiotic Substances 0.000 description 13
- 235000018291 probiotics Nutrition 0.000 description 13
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 230000000529 probiotic effect Effects 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- -1 that is Proteins 0.000 description 9
- 102000003923 Protein Kinase C Human genes 0.000 description 8
- 108090000315 Protein Kinase C Proteins 0.000 description 8
- 208000030961 allergic reaction Diseases 0.000 description 8
- 230000003266 anti-allergic effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 101150056637 Hrh2 gene Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000021472 generally recognized as safe Nutrition 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 241000186840 Lactobacillus fermentum Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 4
- 241000909368 Aquilegia reuteri Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 206010016946 Food allergy Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241001135786 Lactobacillus cerevisiae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 241000194020 Streptococcus thermophilus Species 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960001803 cetirizine Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 3
- 244000281762 Chenopodium ambrosioides Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101100442557 Lactobacillus sp. (strain 30a) hdcA gene Proteins 0.000 description 3
- 241000186783 Lactobacillus vaginalis Species 0.000 description 3
- 241001456524 Lactobacillus versmoldensis Species 0.000 description 3
- 241000194036 Lactococcus Species 0.000 description 3
- 241000192132 Leuconostoc Species 0.000 description 3
- 241000192001 Pediococcus Species 0.000 description 3
- 241000722257 Pelagirhabdus fermentum Species 0.000 description 3
- 206010048908 Seasonal allergy Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 235000003484 annual ragweed Nutrition 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000006263 bur ragweed Nutrition 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 235000003488 common ragweed Nutrition 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 235000009736 ragweed Nutrition 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 241000193798 Aerococcus Species 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193836 Atopobium rimae Species 0.000 description 2
- 241000206594 Carnobacterium Species 0.000 description 2
- 241000726768 Carpinus Species 0.000 description 2
- 241000218645 Cedrus Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 240000005109 Cryptomeria japonica Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102100026167 Fez family zinc finger protein 2 Human genes 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 2
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 2
- 102000000543 Histamine Receptors Human genes 0.000 description 2
- 108010002059 Histamine Receptors Proteins 0.000 description 2
- 241001507052 Lactobacillus algidus Species 0.000 description 2
- 241000186713 Lactobacillus amylovorus Species 0.000 description 2
- 241000954248 Lactobacillus apodemi Species 0.000 description 2
- 241000186723 Lactobacillus bifermentans Species 0.000 description 2
- 241000186679 Lactobacillus buchneri Species 0.000 description 2
- 241000489238 Lactobacillus camelliae Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241000186842 Lactobacillus coryniformis Species 0.000 description 2
- 241000218492 Lactobacillus crispatus Species 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 241000790171 Lactobacillus diolivorans Species 0.000 description 2
- 241001026944 Lactobacillus equigenerosi Species 0.000 description 2
- 241001070017 Lactobacillus fermentum ATCC 14931 Species 0.000 description 2
- 241000015236 Lactobacillus fornicalis Species 0.000 description 2
- 241000186839 Lactobacillus fructivorans Species 0.000 description 2
- 241000370757 Lactobacillus fuchuensis Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 241000316283 Lactobacillus gastricus Species 0.000 description 2
- 241000950383 Lactobacillus ghanensis Species 0.000 description 2
- 241000925032 Lactobacillus harbinensis Species 0.000 description 2
- 241000914114 Lactobacillus hayakitensis Species 0.000 description 2
- 241001468190 Lactobacillus homohiochii Species 0.000 description 2
- 241001343376 Lactobacillus ingluviei Species 0.000 description 2
- 241001640457 Lactobacillus intestinalis Species 0.000 description 2
- 241001561398 Lactobacillus jensenii Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000108055 Lactobacillus kefiranofaciens Species 0.000 description 2
- 241001134654 Lactobacillus leichmannii Species 0.000 description 2
- 241000751214 Lactobacillus malefermentans Species 0.000 description 2
- 241000394636 Lactobacillus mucosae Species 0.000 description 2
- 241001635183 Lactobacillus nagelii Species 0.000 description 2
- 241000468580 Lactobacillus namurensis Species 0.000 description 2
- 241001150383 Lactobacillus oligofermentans Species 0.000 description 2
- 241000216456 Lactobacillus panis Species 0.000 description 2
- 241001105994 Lactobacillus parabrevis Species 0.000 description 2
- 241001643453 Lactobacillus parabuchneri Species 0.000 description 2
- 241000972176 Lactobacillus paracollinoides Species 0.000 description 2
- 241000692139 Lactobacillus rennini Species 0.000 description 2
- 241001424195 Lactobacillus satsumensis Species 0.000 description 2
- 241001599932 Lactobacillus spicheri Species 0.000 description 2
- 241000577554 Lactobacillus zeae Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101100038261 Methanococcus vannielii (strain ATCC 35089 / DSM 1224 / JCM 13029 / OCM 148 / SB) rpo2C gene Proteins 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
- 241000202223 Oenococcus Species 0.000 description 2
- 208000008267 Peanut Hypersensitivity Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 241000500334 Tetragenococcus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960001271 desloratadine Drugs 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 201000004338 pollen allergy Diseases 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 101150085857 rpo2 gene Proteins 0.000 description 2
- 101150090202 rpoB gene Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- MFVJXLPANKSLLD-UHFFFAOYSA-N 6-[2-[4-[(4-fluorophenyl)-phenylmethylidene]-1-piperidinyl]ethyl]-7-methyl-5-thiazolo[3,2-a]pyrimidinone Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=CC=C1 MFVJXLPANKSLLD-UHFFFAOYSA-N 0.000 description 1
- 241000219496 Alnus Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000910112 Ataliothrips reuteri Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000723437 Chamaecyparis Species 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100030221 Diacylglycerol kinase theta Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 208000004739 Egg Hypersensitivity Diseases 0.000 description 1
- 241001430190 Eggerthia catenaformis Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010014095 Histidine decarboxylase Proteins 0.000 description 1
- 102100037095 Histidine decarboxylase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 241000186778 Kandleria vitulina Species 0.000 description 1
- 241000186717 Lactobacillus acetotolerans Species 0.000 description 1
- 241000110061 Lactobacillus acidifarinae Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 241000186716 Lactobacillus agilis Species 0.000 description 1
- 241000186714 Lactobacillus amylophilus Species 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 241000316282 Lactobacillus antri Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 241001468197 Lactobacillus collinoides Species 0.000 description 1
- 241000933456 Lactobacillus composti Species 0.000 description 1
- 241000861211 Lactobacillus crustorum Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000500356 Lactobacillus dextrinicus Species 0.000 description 1
- 241000186841 Lactobacillus farciminis Species 0.000 description 1
- 241000831741 Lactobacillus farraginis Species 0.000 description 1
- 241001493843 Lactobacillus frumenti Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241000866684 Lactobacillus graminis Species 0.000 description 1
- 241000111368 Lactobacillus hammesii Species 0.000 description 1
- 241000186685 Lactobacillus hilgardii Species 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 241000316281 Lactobacillus kalixensis Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 241000674808 Lactobacillus kitasatonis Species 0.000 description 1
- 241000520745 Lactobacillus lindneri Species 0.000 description 1
- 241000016642 Lactobacillus manihotivorans Species 0.000 description 1
- 241000414465 Lactobacillus mindensis Species 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 241000938545 Lactobacillus nantensis Species 0.000 description 1
- 241000186784 Lactobacillus oris Species 0.000 description 1
- 241000692795 Lactobacillus pantheris Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000831743 Lactobacillus parafarraginis Species 0.000 description 1
- 241001643449 Lactobacillus parakefiri Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241001448603 Lactobacillus perolens Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241001495404 Lactobacillus pontis Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241001438705 Lactobacillus rogosae Species 0.000 description 1
- 241000602084 Lactobacillus rossiae Species 0.000 description 1
- 241000318646 Lactobacillus saerimneri Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000915257 Lactobacillus secaliphilus Species 0.000 description 1
- 241001643448 Lactobacillus suebicus Species 0.000 description 1
- 241000316280 Lactobacillus ultunensis Species 0.000 description 1
- 241000751212 Lactobacillus vaccinostercus Species 0.000 description 1
- 241000692127 Lactobacillus vini Species 0.000 description 1
- 241000110060 Lactobacillus zymae Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 208000002366 Nut Hypersensitivity Diseases 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 241000209466 Platanus Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 208000008555 Shellfish Hypersensitivity Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000204117 Sporolactobacillus Species 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 241000907897 Tilia Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 241000750042 Vini Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960003166 bromazine Drugs 0.000 description 1
- NUNIWXHYABYXKF-UHFFFAOYSA-N bromazine Chemical compound C=1C=C(Br)C=CC=1C(OCCN(C)C)C1=CC=CC=C1 NUNIWXHYABYXKF-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229960002691 dexbrompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229950000472 embramine Drugs 0.000 description 1
- URSRSKSNFPUKGH-UHFFFAOYSA-N embramine Chemical compound C=1C=C(Br)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 URSRSKSNFPUKGH-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 201000005318 fish allergy Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229960003941 orphenadrine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650620 | 2016-05-09 | ||
| SE1650620-6 | 2016-05-09 | ||
| PCT/SE2017/050455 WO2017196235A1 (en) | 2016-05-09 | 2017-05-08 | Selection of bacterial strains useful in allergy treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520801A JP2019520801A (ja) | 2019-07-25 |
| JP2019520801A5 JP2019520801A5 (enExample) | 2020-06-18 |
| JP7030716B2 true JP7030716B2 (ja) | 2022-03-07 |
Family
ID=58873850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558668A Active JP7030716B2 (ja) | 2016-05-09 | 2017-05-08 | アレルギー治療に有用な細菌株の選択 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11135255B2 (enExample) |
| EP (1) | EP3454874A1 (enExample) |
| JP (1) | JP7030716B2 (enExample) |
| CN (1) | CN109195612A (enExample) |
| AU (1) | AU2017262408A1 (enExample) |
| BR (1) | BR112018072511A2 (enExample) |
| CA (1) | CA3023867A1 (enExample) |
| CL (1) | CL2018003167A1 (enExample) |
| MX (1) | MX392754B (enExample) |
| SG (1) | SG11201809551TA (enExample) |
| WO (1) | WO2017196235A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4081229A1 (en) * | 2019-12-24 | 2022-11-02 | Iowa State University Research Foundation, Inc. | Control of histamine to promote health and control enterocolitis using probiotic compositions and/or histamine degrading enzymes |
| JP7515153B2 (ja) * | 2020-03-06 | 2024-07-12 | 学校法人麻布獣医学園 | 乳酸菌含有組成物 |
| CN113073066B (zh) * | 2021-04-16 | 2022-01-04 | 段云峰 | 罗伊氏乳杆菌及其应用、组合物、药物和食品 |
| CN114317326B (zh) * | 2021-12-06 | 2023-09-12 | 浙江工商大学 | 一种用于缓解过敏反应的清酒乳杆菌及制备方法 |
| CN115025130A (zh) * | 2022-06-02 | 2022-09-09 | 广东南芯医疗科技有限公司 | 罗伊氏乳杆菌e9在制备治疗或预防过敏性疾病药物中的应用 |
| CN116376758B (zh) * | 2023-03-15 | 2024-07-02 | 广东南芯医疗科技有限公司 | 詹氏乳杆菌ls06及其在制备治疗或预防过敏性疾病药物中的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008127365A (ja) | 2006-11-24 | 2008-06-05 | Kowa Co | アレルギー性疾患の予防及び／又は治療剤 |
| JP2008519794A (ja) | 2004-11-11 | 2008-06-12 | アージェンタ・ディスカバリー・リミテッド | ピリミジン化合物 |
| JP2011254773A (ja) | 2010-06-11 | 2011-12-22 | Bio Plan:Kk | 乳酸菌の菌株及びこれを利用したアレルギー抑制剤 |
| JP2014520559A (ja) | 2011-07-21 | 2014-08-25 | バイオガイア・エイビー | 細菌性ヒスタミンの産生及び使用 |
| JP2015019770A (ja) | 2013-07-18 | 2015-02-02 | 国立大学法人徳島大学 | 鼻炎の予防治療装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK154078C (da) * | 1981-02-06 | 1989-05-22 | Ucb Sa | Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf |
| JP4212838B2 (ja) * | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
| AU2002951270A0 (en) * | 2002-09-06 | 2002-09-19 | Vri Biomedical Ltd | Probiotic Bacterium and Methods of Use |
| KR100507417B1 (ko) * | 2003-01-27 | 2005-08-10 | (주) 피엘바이오 | 알레르기 질환 예방 및 치료 기능을 가진 유산균과 이를 함유한 항알레르기 제품 |
| EP2674493B1 (en) * | 2006-04-13 | 2017-12-27 | Arrowhead Research Corporation | RNAi-mediated inhibition of histamine receptor H1-related conditions |
| US20110217290A1 (en) * | 2008-08-18 | 2011-09-08 | Manel Jordana | Treatment and/or prevention of peanut induced anaphylaxis |
| WO2012012390A1 (en) * | 2010-07-19 | 2012-01-26 | Marvphyt Development Llc | Botanical composition and methods of manufacture and use |
| WO2014130759A1 (en) * | 2013-02-21 | 2014-08-28 | University Of Rochester | Methods of using histamine receptor agonists and antagonists |
| SG11201705479UA (en) * | 2015-03-26 | 2017-10-30 | Biogaia Ab | Histamine-producing bacterial strains and their use in cancer |
-
2017
- 2017-05-08 BR BR112018072511A patent/BR112018072511A2/pt not_active Application Discontinuation
- 2017-05-08 JP JP2018558668A patent/JP7030716B2/ja active Active
- 2017-05-08 SG SG11201809551TA patent/SG11201809551TA/en unknown
- 2017-05-08 WO PCT/SE2017/050455 patent/WO2017196235A1/en not_active Ceased
- 2017-05-08 MX MX2018013660A patent/MX392754B/es unknown
- 2017-05-08 US US16/099,258 patent/US11135255B2/en active Active
- 2017-05-08 EP EP17727008.9A patent/EP3454874A1/en not_active Ceased
- 2017-05-08 CA CA3023867A patent/CA3023867A1/en active Pending
- 2017-05-08 AU AU2017262408A patent/AU2017262408A1/en not_active Abandoned
- 2017-05-08 CN CN201780028567.1A patent/CN109195612A/zh active Pending
-
2018
- 2018-11-08 CL CL2018003167A patent/CL2018003167A1/es unknown
-
2021
- 2021-08-31 US US17/462,227 patent/US12201656B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008519794A (ja) | 2004-11-11 | 2008-06-12 | アージェンタ・ディスカバリー・リミテッド | ピリミジン化合物 |
| JP2008127365A (ja) | 2006-11-24 | 2008-06-05 | Kowa Co | アレルギー性疾患の予防及び／又は治療剤 |
| JP2011254773A (ja) | 2010-06-11 | 2011-12-22 | Bio Plan:Kk | 乳酸菌の菌株及びこれを利用したアレルギー抑制剤 |
| JP2014520559A (ja) | 2011-07-21 | 2014-08-25 | バイオガイア・エイビー | 細菌性ヒスタミンの産生及び使用 |
| JP2015019770A (ja) | 2013-07-18 | 2015-02-02 | 国立大学法人徳島大学 | 鼻炎の予防治療装置 |
Non-Patent Citations (2)
| Title |
|---|
| Ganesh, B. P. et al，hdcA+ L. reuteri 6475 inhibits H1R downstream signaling via dagK and causes immunosuppression of intestinal epithelium in gnotobiotic mice，FASEB J., [online]，2016年04月01日，Vol. 30, Issue S1，p. 1018.1，https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.30.1_supplement.1018.1，Internet, [retrieved on 2021.6.14] |
| Zhong, X. et al.，Diacylglycerol Kinase Deficiency Increases the Peanut Allergic Response in Mice，J. Allergy Clin. Immunol.，2008年，Vol. 121, Issue 2, Supplement 1，p. S97; 376 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017196235A1 (en) | 2017-11-16 |
| CN109195612A (zh) | 2019-01-11 |
| US20190142877A1 (en) | 2019-05-16 |
| US12201656B2 (en) | 2025-01-21 |
| EP3454874A1 (en) | 2019-03-20 |
| MX392754B (es) | 2025-03-24 |
| MX2018013660A (es) | 2019-02-28 |
| CL2018003167A1 (es) | 2018-12-21 |
| AU2017262408A1 (en) | 2018-11-15 |
| CA3023867A1 (en) | 2017-11-16 |
| US11135255B2 (en) | 2021-10-05 |
| US20220008491A1 (en) | 2022-01-13 |
| SG11201809551TA (en) | 2018-11-29 |
| JP2019520801A (ja) | 2019-07-25 |
| BR112018072511A2 (pt) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7030716B2 (ja) | アレルギー治療に有用な細菌株の選択 | |
| JP7292877B2 (ja) | １型糖尿病を処置するための組成物および方法 | |
| JP6641262B2 (ja) | ポリペプチド及びイムノモジュレーション | |
| KR101473058B1 (ko) | 과민성 대장 증후군 예방 또는 치료용 조성물 | |
| JP2021522867A (ja) | ラクトバチルス・パラカゼイ株及びその使用 | |
| JP4942831B2 (ja) | 抗アレルギー用組成物 | |
| US12359210B2 (en) | Genetically modified bacteria stably expressing IL-10 and insulin | |
| KR20190056387A (ko) | 점막부착성 미생물 | |
| BRPI0809448A2 (pt) | Cepas de bifidobacterium probióticas | |
| JP6669703B2 (ja) | 改変されたグラム陽性菌及びその使用 | |
| BR112012011315B1 (pt) | Formulação que compreende cepa de bifidobactéria probiótica | |
| JP2023523221A (ja) | 腸内ビフィズス菌の増殖の刺激 | |
| JP2023501358A (ja) | セロトニン産生細菌 | |
| CN103228143A (zh) | 用于增强肾功能的组合物和方法 | |
| CN113925886B (zh) | 四联活菌组合物的新应用 | |
| CN1760360A (zh) | 发酵乳酸杆菌GM－090及其在刺激INF－γ分泌及/或治疗过敏的用途 | |
| HK40001496A (en) | Selection of bacterial strains useful in allergy treatment | |
| TWI342217B (en) | Anti-allergy microbe, compositions thereof and methods for stimulating cells to secrete interferon-γ using the microbe | |
| Zhang | Intestinal delivery of heterologous peptides with lactobacilli | |
| HK1141554B (en) | Probiotic bifidobacterium strains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200508 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210618 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220125 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220216 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220222 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7030716 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |